Ligand Pharmaceuticals Incorporated

As of June 30, 2026, Ligand Pharmaceuticals Incorporated carries a market capitalization of 5.50B, placing it among publicly traded companies globally. Its enterprise value stands at 5.29B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Ligand Pharmaceuticals Incorporated's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Ligand Pharmaceuticals Incorporated has 19.92M shares outstanding.

As of June 30, 2026, Ligand Pharmaceuticals Incorporated trades at a trailing price-to-earnings ratio of 31.68. The price-to-sales ratio is 21.50, and the price-to-book ratio stands at 6.49.

As of June 30, 2026, Ligand Pharmaceuticals Incorporated trades at an EV/EBITDA multiple of 47.33 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 20.80 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 63.78 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Ligand Pharmaceuticals Incorporated trades at an EV/FCF ratio of 48.38, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 5.29B versus a market cap of 5.50B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Ligand Pharmaceuticals Incorporated maintains a current ratio of 31.18, meaning it holds 31.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 116.94, indicating elevated leverage, while an interest coverage ratio of 20.62 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Ligand Pharmaceuticals Incorporated posted a return on equity (ROE) of 21.96, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 5.34 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 12.58, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 13.80, useful for judging operating efficiency across full business cycles. The company generates approximately 4.87M in revenue per employee across its workforce of 52.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.23 indicates how many times Ligand Pharmaceuticals Incorporated sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Ligand Pharmaceuticals Incorporated recorded 35.66M in income tax expense. That works out to an effective tax rate of 17.12, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 208.29M, leaving 172.63M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Ligand Pharmaceuticals Incorporated's stock has gained approximately 73.58% over the past 52 weeks. The 50-day moving average sits at 257.08, while the 200-day moving average is 217.00.

Over the twelve months ended June 30, 2026, Ligand Pharmaceuticals Incorporated generated 254.31M in revenue and converted that into 172.63M in net income, yielding earnings per share of 8.27. EBITDA reached 111.73M, while operating income came in at 87.61M.

As of June 30, 2026, Ligand Pharmaceuticals Incorporated holds 1.20B in cash and equivalents against 990.36M in total debt, resulting in a net debt position of 104.94M. Total book value stands at 846.87M, with working capital of 1.23B providing operational flexibility.

Ligand Pharmaceuticals Incorporated produced 115.29M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -10.47M in capital expenditures, free cash flow totaled 104.82M - equivalent to 5.29 per share.

Over the twelve months ended June 30, 2026, Ligand Pharmaceuticals Incorporated posted a gross margin of 95.43, reflecting its pricing power and cost economics. The operating margin of 34.45 and net profit margin of 67.88 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 1.82, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -15.13, meaning Ligand Pharmaceuticals Incorporated raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Ligand Pharmaceuticals Incorporated's most recent stock split took place on November 19, 2010 with a 6:1 split ratio.

As of June 30, 2026, Ligand Pharmaceuticals Incorporated has an Altman Z-Score of 4.76, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.